AIM
ACET icon

Alambic Investment Management’s Adicet Bio ACET Stock Holding History

Alambic Investment Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-979
Closed -$113K – 164
2020
Q1 		$113K Buy
+979
New +$145K 0.27% 122

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Alambic Investment Management's ACET Position: Q2 2020 in Review

Alambic Investment Management sold out of Adicet Bio (ACET) in Q2 2020, closing a stake of 979 shares — an estimated $113K sold.

Alambic Investment Management first reported a position in ACET in Q1 2020 and held it in 1 quarter. The position peaked at $113K in Q1 2020. 53 funds tracked by Wall St. Rank hold ACET as of Q2 2020.

  • Alambic Investment Management reported no remaining Adicet Bio position as of Q2 2020 after selling out during the quarter.
  • Alambic Investment Management sold 979 Adicet Bio shares in Q2 2020, an estimated $113K.
  • Alambic Investment Management first reported a position in Adicet Bio in Q1 2020 and held it in 1 quarter.
  • Alambic Investment Management's Adicet Bio position peaked at $113K in Q1 2020.
  • 53 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2020.

Based on Alambic Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.